Publicaciones en las que colabora con JUAN TAMARGO MENÉNDEZ (35)

2023

  1. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

2016

  1. Nav1.5 N-terminal domain binding to α1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels

    Cardiovascular Research, Vol. 110, Núm. 2, pp. 279-290

  2. Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L

    Cardiovascular Research, Vol. 109, Núm. 3, pp. 431-441

2014

  1. Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents

    Cardiovascular Research, Vol. 104, Núm. 2, pp. 337-346

2013

  1. Chronic atrial fibrillation up-regulates β1-Adrenoceptors affecting repolarizing currents and action potential duration

    Cardiovascular Research, Vol. 97, Núm. 2, pp. 379-388

  2. Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore

    Biochemical Pharmacology, Vol. 86, Núm. 2, pp. 267-278

2011

  1. Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome

    Heart Rhythm, Vol. 8, Núm. 3, pp. 463-470

2010

  1. Cardiac electrophysiological effects of nitric oxide

    Cardiovascular Research, Vol. 87, Núm. 4, pp. 593-600

  2. Clinical Pharmacology of Ranolazine, a Novel Compound for Treating Chronic Stable Angina

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. SUPPL. 2

  3. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner

    Cardiovascular Research, Vol. 85, Núm. 1, pp. 56-67

  4. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner

    Journal of Molecular and Cellular Cardiology, Vol. 48, Núm. 1, pp. 201-210

  5. Farmacología clínica de la ranolazina, un nuevo fármaco en el tratamiento de la angina crónica estable

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. 2, pp. 41-54

  6. Farmacología clínica de la ranolazina, un nuevo fármaco en el tratamiento de la angina crónica estable

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. 1

  7. Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Núm. 35, pp. 15631-15636

  8. In Humans, Chronic Atrial Fibrillation Decreases the Transient Outward Current and Ultrarapid Component of the Delayed Rectifier Current Differentially on Each Atria and Increases the Slow Component of the Delayed Rectifier Current in Both

    Journal of the American College of Cardiology, Vol. 55, Núm. 21, pp. 2346-2354

2009

  1. IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation

    Expert Opinion on Investigational Drugs, Vol. 18, Núm. 4, pp. 399-416

  2. Investigational positive inotropic agents for acute heart failure

    Cardiovascular and Hematological Disorders - Drug Targets, Vol. 9, Núm. 3, pp. 193-205

  3. Nitric oxide increases cardiac ik1 by nitrosylation of cysteine 76 of Kir2.1 Channels

    Circulation Research, Vol. 105, Núm. 4, pp. 383-392

2008

  1. Effects of MiRP1 and DPP6 β-subunits on the blockade induced by flecainide of K V4.3/KChIP2 channels

    British Journal of Pharmacology, Vol. 154, Núm. 4, pp. 774-786

  2. Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1)

    Cardiovascular Research, Vol. 80, Núm. 3, pp. 375-384